Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

This research is an experimental study with a randomized controlled clinical design involving two intervention groups: one receiving secretome injections and the other receiving intradermal platelet-rich plasma injections. Evaluations are conducted by measuring hair density and the terminal-to-vellus hair ratio before and after treatment using trichoscopy/dermoscopy.

• Secretome (Biological): UC-MSC secretome was injected intradermally into the scalp at the alopecia site, with injections spaced 1 cm apart and administered every 2 weeks for 8 weeks
• Platelet-Rich Plasma (PRP) Injections (Biological): The centrifuged plasma solution was injected intradermally into the scalp at the alopecia site, with 0.1 ml per injection point spaced 1 cm apart, administered every 2 weeks for 8 weeks

Primary outcomes

• Terminal-to-Vellus Hair Ratio [Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)]: The ratio of terminal hair (thick, pigmented hair, diameter >40 micrometer) to vellus hair (fine hair, diameter <30 micrometer) in areas of androgenetic alopecia
• Hair density [Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)]: The number of hairs per specific scalp area was measured in hairs/cm²

Sex: All, ages: 25 Years to 59 Years

Inclusion Criteria:

* Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
* Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
* Female patients who are not currently pregnant or breastfeeding.
* Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
* Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
* Patients who are proficient in Indonesian and willing to provide written informed consent.

Exclusion Criteria:

* Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
* Patients presenting with types of hair loss other than androgenetic alopecia.
* Patients currently undergoing therapy with 5-alpha reductase inhibitors.
* Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
* Patients with active infections and/or active dermatitis on the scalp.
* Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
* History of hypertrophic scarring or blood clotting (coagulation) disorders.
* Patients unable to complete the research procedures in their entirety.